A nested randomised trial of the effect of tranexamic acid on intracranial haemorrhage and infarction in traumatic brain injury (CRASH-3 trial intracranial bleeding mechanistic study): Statistical analysis plan. by Mahmood, Abda et al.
LSHTM Research Online
Mahmood, Abda; Roberts, Ian; Shakur-Still, Haleema; (2018) A nested randomised trial of the effect
of tranexamic acid on intracranial haemorrhage and infarction in traumatic brain injury (CRASH-3
trial intracranial bleeding mechanistic study): Statistical analysis plan. Wellcome open research, 3.




Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.






   A nested randomised trial of the effect of tranexamic acid
on intracranial haemorrhage and infarction in traumatic brain
injury (CRASH-3 trial intracranial bleeding mechanistic study):
 Statistical analysis plan [version 2; peer review: 2 approved, 2
approved with reservations]


























































 13 Aug 2018,  :99 (First published: 3
)https://doi.org/10.12688/wellcomeopenres.14731.1
 08 Jan 2019,  :99 (Latest published: 3
)https://doi.org/10.12688/wellcomeopenres.14731.2
v2
Page 1 of 19




 Abda Mahmood ( )Corresponding author: Abda.Mahmood@lshtm.ac.uk










The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 © 2019 Mahmood A  . This is an open access article distributed under the terms of the  ,Copyright: et al Creative Commons Attribution Licence
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Mahmood A, Roberts I and Shakur-Still H. How to cite this article: A nested randomised trial of the effect of tranexamic acid on
intracranial haemorrhage and infarction in traumatic brain injury (CRASH-3 trial intracranial bleeding mechanistic study): Statistical
 Wellcome Open Research 2019,  :99 (analysis plan [version 2; peer review: 2 approved, 2 approved with reservations] 3
)https://doi.org/10.12688/wellcomeopenres.14731.2
 13 Aug 2018,  :99 ( ) First published: 3 https://doi.org/10.12688/wellcomeopenres.14731.1
Page 2 of 19
Wellcome Open Research 2019, 3:99 Last updated: 06 JUN 2019
Introduction
Worldwide over 50 million people experience traumatic brain 
injury (TBI) every year1. TBI is the leading cause of death and 
disability in young adults2, particularly in low-income and 
middle-income countries where rates of road traffic crashes are 
increasing3. Falls are the most frequent cause of TBI in high-
income countries4. Intracranial bleeding is common after TBI, 
mostly in the first few hours after injury5. The larger the bleed 
the greater the risk of death and long-term disability6. To improve 
outcome from this life threatening and potentially disabling 
condition, effective treatments are needed to reduce intracranial 
haemorrhage expansion.
The permeability of the blood-brain barrier is compromised after 
TBI7. Tranexamic acid could penetrate the blood-brain-barrier 
to enter the cerebrospinal fluid8,9, inhibit the enzymatic break-
down of fibrin blood clots and reduce intracranial haemorrhage 
expansion. A recent systematic review identified two completed 
randomised trials of tranexamic acid in TBI10. When the two 
trials were combined in a meta-analysis (n=478), there was a 
statistically significant reduction in intracranial haemorrhage 
growth (RR 0.75, 95% CI 0.58–0.98; P = 0.03) and mortality 
(RR 0.63, 95% CI 0.40–0.99; P = 0.05) with tranexamic acid. 
Neither trial found evidence for an increased risk of infarction 
with tranexamic acid (RR 0.51, 95% CI 0.20–1.32; P = 0.17)11 
(0 infarcts – tranexamic acid group, 3 infarcts – placebo group)12. 
However, the confidence intervals are wide and the quality of 
this evidence is low. Therefore, the effect of tranexamic acid on 
mortality, intracranial bleeding and infarction in TBI remains 
uncertain.
The CRASH-3 trial, with a planned sample size of 13,000 
patients, will be the largest randomised trial into the effect of 
tranexamic acid in isolated TBI13. The CRASH-3 trial is a pro-
spective, international, multi-centre, parallel group, placebo- 
controlled randomised trial that examines the effects of 
tranexamic acid on death and disability in TBI. Patients who are 
within 8 hours of their TBI and have intracranial bleeding on 
a computed tomography (CT) scan or a Glasgow Coma Score 
(GCS) of 12 or less, and no significant extra-cranial bleeding, 
are potentially eligible for inclusion in the CRASH-3 trial. The 
original 8 hour time window for recruitment was restricted to 
3 hours of injury in 2016 in order to reliably examine the effect 
of tranexamic acid given soon after injury. Eligible patients are 
randomly allocated (1:1) to receive tranexamic acid or matching 
placebo (0.9% sodium chloride). The 1 gram loading dose of the 
trial treatment is administered by intravenous injection within min-
utes of randomisation in hospital. The 1 gram maintenance dose 
is administered by intravenous infusion as soon as the loading 
dose has completed. Tranexamic acid or placebo are given as 
an additional treatment to the routine management of TBI. The 
aims and methods for the CRASH-3 trial are presented in detail 
elsewhere13.
The CRASH-3 trial is based on the premise that intracranial bleed-
ing contributes to head injury death and disability in patients 
with TBI. By inhibiting fibrinolysis, tranexamic acid is expected 
to reduce the extent of intracranial bleeding14. Therefore, we 
expect to see less intracranial bleeding in head CT scans of 
patients treated with tranexamic acid, particularly in those treated 
soon after injury when the risk of haemorrhage expansion is 
greatest5. On the other hand, tranexamic acid might increase the 
risk of cerebral thrombosis and infarction in TBI patients, poten-
tially worsening neurological outcome15–17. In this case, we 
expect to see more infarcts in patients treated with tranexamic 
acid, particularly in those treated after a prolonged period after 
injury when there is an increased risk of thrombotic disseminated 
intravascular coagulation15.
The CRASH-3 Intracranial Bleeding Mechanistic Study (IBMS) 
is a randomised trial nested within the CRASH-3 trial and exam-
ines the effect of tranexamic acid on intracranial bleeding and 
infarction (protocol version 1.3 currently in use)18. The IBMS 
evaluates the effect of tranexamic acid on bleeding expansion 
using a validated method (ABC/2)19 to measure the total bleeding 
volume on routinely collected CT scans done soon after ran-
domisation. The blinded data from ≈1,000 patients in the IBMS 
so far suggests that this scan is done within a mean of 44 hours 
after randomisation. Bleeding is well visualised on CT in the 
early stage of injury20. Because infarction takes longer to 
            Amendments from Version 1
The main changes from Version 1 of the CRASH-3 Trial IBMS SAP 
and Version 2 are:
1) Primary outcome – a comparison of intra-parenchymal 
bleeding volume between treatment groups (rather than total 
intracranial bleeding volume).
2) Primary analysis – linear mixed model with pre-randomisation 
intra-parenchymal bleeding volume as an outcome (rather than 
previously proposed ANCOVA model that did not include pre-
randomisation bleeding) (as per reviewer comments).
3) Elaborated on the proposed sensitivity analysis relative to the 
MNAR assumption (as per reviewer comments).
3) Other sensitivity analyses –
a. For the primary analysis assume missing data are MAR 
(assumption of linear mixed model) and do sensitivity analyses 
assuming they are MCAR or MNAR. 
b. Remove neurosurgery patients from the primary analysis to 
reduce null bias from the bleeding related effects of neurosurgery 
and not TXA.
c. Remove neurosurgery patients from the cerebral infarction 
analysis to reduce null bias from infarction related effects of 
neurosurgery and not TXA.
4) Composite “poor outcome” (progressive bleeding, new 
bleeding, infarction, death or the need for neurosurgery). This 
would align the outcomes more with the main CRASH-3 trial.
5) Updated sample size and power calculation (as per reviewer 
comments).
The rationale for changes have been incorporated into the 
updated version of the SAP.
See referee reports
REVISED
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manifest on CT imaging21, the effect of tranexamic acid on inf-
arction is examined using all routinely collected brain imaging 
(including magnetic resonance imaging) done within 28 days of 
randomisation. The IBMS will provide information on the mech-
anism of action of tranexamic acid in TBI and could facilitate 
the generalisation of trial results22. This pre-specified statistical 
analysis plan is a technical extension of the published protocol19.
Trial methods
The aims and methods for the IBMS are presented in detail 
elsewhere18.
Aim
The IBMS aims to examine the mechanism by which tranexamic 
acid exerts its effects in patients with isolated TBI. Specifi-
cally, we will assess the effect of tranexamic acid on intracranial 
bleeding and infarction.
Trial design and eligibility criteria
The IBMS is a randomised, placebo-controlled, parallel group, 
international, multi-centre, double-blind trial nested within 
the CRASH-3 trial. Patients who fulfil the eligibility criteria 
for the CRASH-3 trial, with a GCS of 12 or less or intracra-
nial bleeding on a CT scan done before randomisation, are 
eligible for inclusion in the IBMS.
Trial registration
The CRASH-3 trial was prospectively registered at the Inter-
national Standard Randomised Controlled Trials registry 
(ISRCTN15088122) on 19 July 2011, and ClinicalTrials.gov 
on 25 July 2011 (NCT01402882). The registries were updated 
with details for the IBMS on 20 December 2016.
Ethical approval
The UK Medical Research and Ethics Committee and Health 
Research Authority reviewed the protocol and supporting 
documents for the IBMS and provided a favourable ethical 
opinion on 8 June 2016 (Research Ethics Committee Refer-
ence 12/EE/0274). All participating UK hospitals have provided 
Research and Development approvals and letters of access for the 
IBMS to be conducted at their respective sites. The Malaysian 
Medical Research and Ethics Committee reviewed the protocol 
and supporting documents for the IBMS and provided favour-
able ethical opinion on 16 May 2017 (Reference (25) KKM/ 
NIHSEC/P12-476). All relevant national and local ethical approv-
als will be gained from additional sites. Favourable ethical opin-
ion was received from the Observational/Interventions Research 
Ethics Committee at LSHTM on 24 May 2016 (Reference 
11535). The relevant Medical Research and Ethics Committees 
will review important protocol modifications for approval before 
implementation, and registries updated as appropriate.
Consent to participate
TBI patients are physically and mentally incapable of providing 
informed consent to participate in a clinical trial. As acknowl-
edged in the Declaration of Helsinki, patients who are incapable 
of giving consent are an exception to the general rule of informed 
consent in clinical trials23. In the CRASH-3 trial, patients are 
unable to provide consent and so consent is sought from the 
patient’s relative, legal representative or the responsible clini-
cian. If and when the patient regains capacity to provide informed 
consent, they are informed about the trial and written consent 
sought to continue their participation in the trial. If a patient 
or patient representative declines consent, they are with-
drawn from the trial. For patients who were included in the 
trial but did not regain capacity, written informed consent is 
sought from a relative or legal representative. Written informed 
consent from patients, their relatives, legal representatives or 
the responsible clinician includes consent for the publication of 
anonymised patient data. The requirements of relevant local and 
national ethics committees are adhered to at all times.
The CRASH-3 trial includes consent to extract data from 
patient medical records. Collecting brain imaging data for the 
IBMS is consistent with the consent procedure used in the 
CRASH-3 trial. It would be impractical to re-consent patients or 
relatives/legal representatives to brain imaging, particularly for 
patients who have deceased or are disabled as a result of their 
injuries where re-consent would be distressing and unwelcome. 
The LSHTM and national Ethics Committees extended their 
approvals to extract brain imaging data from CRASH-3 trial 
patients without further patient consent. Patients who withdrew 
from the main CRASH-3 trial would not be included in the IBMS.
Participating hospitals
The hospitals participating in the IBMS were selected based 
on the number of patients enrolled in the CRASH-3 trial, the 
availability of electronic imaging at site and the willingness of 
the trial principal investigator at site to take part. We invited 
ten of the highest recruiting CRASH-3 trial hospitals in the 
United Kingdom (UK) to take part (Queen Elizabeth Hospital, 
Birmingham; Royal London Hospital; University Hospital 
Coventry; Salford Royal Hospital; St George’s Hospital, London; 
King’s College Hospital, London; St Mary’s Hospital, London; 
Addenbrooke’s Hospital, Cambridge; John Radcliffe Hospital, 
Oxford, Southmead Hospital, North Bristol). We also invited 
four hospitals in Malaysia to take part: Hospital Sungai Buloh, 
Penang General Hospital, Hospital Sultanah Nur Zahirah and 
Hospital Sultanah Bahiyah. We will report all participating sites in 
the final results publication.
Sample size
A trial with about 1,750 patients would have 95% power (at 
alpha = 0.05) to detect the expected 15% reduction in intracranial 
bleeding volume with tranexamic acid11. We expect around 75% 
of patients (n=1300) will be randomised within three hours of 
injury, and this sample will have 90% power to detect the expected 
treatment effect. Therefore, we will continue to collect data for 
the IBMS until we reach 2,000 patients or the CRASH-3 trial 
completes recruitment (scheduled end date: 31 January 2019).
Interim analyses and unblinding
The treatment allocation is double-blinded such that trial team 
members, outcome assessors and patients are unaware of 
whether a trial patient will receive tranexamic acid or placebo. 
There are no interim analyses planned. The final analysis of the 
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unblinded results will take place after recruitment is complete, 
the data have been cleaned and the trial database has been locked 
as per the procedures detailed in the Data Management Plan 
(DMP) (version 1.0) and protocol18.
Data management and integrity
All trial data are managed in accord with the IBMS DMP which 
is stored in the Trial Master File. The DMP working procedures 
are produced in conjunction with the London School of Hygiene 
and Tropical Medicine (LSHTM) policies and procedures, 
the Clinical Trials Unit and trial specific working procedures, 
and regulatory requirements. The web database was built to 
comply with ICH-GCP guidelines and uses MySQL for data 
storage. Hypertext Preprocessor (PHP) was used to develop the 
dynamic web pages for the user interface.
Data are collected at each participating site and directly uploaded 
into the web database. A number of computerised validation 
checks have been built into the database to ensure all required 
fields are complete and irregular entries are flagged. In rare 
cases of poor internet connection or inadequate facilities, paper 
versions of the Case Report Forms (CRFs) are completed and 
transcribed into the web database as soon as possible. A delegate 
cross-checks the transcription between paper and web CRFs 
and any detected errors are amended on paper and/or web CRFs 
immediately. Any revisions to a submitted form are saved auto-
matically in a database log with details of who edited the data and 
when edits were made. Any changes made from the initial form 
submission are highlighted in each amended version of a form. 
All other data checks and cleaning are performed by the IBMS 
lead. This includes using a download report facility within the 
database to review the data for inconsistencies and resolve que-
ries as per the procedures detailed in the DMP. The final database 
lock will take place at the end of the trial within three months of 
the end of data collection. Data will be exported for statistical 
analysis in Stata Version 15 [StataCorp LP, College Station, Texas, 
USA].
Primary outcome
The mean volume of intra-parenchymal bleeding will be compared 
between trial arms in patients randomised within three hours of 
injury, adjusting for prognostic covariates.
In the original IMBS protocol18, we said the total volume of 
intracranial bleeding would be compared between treatment 
groups. Since publishing the protocol, we have collected blinded 
data from 1700 trial patients, which suggest that any effect of 
tranexamic acid on intracranial bleeding expansion may only be 
reliably detected in intra-parenchymal bleeds. Intra-parenchymal 
bleeds are less likely to be surgically evacuated compared to 
subdural and epidural bleeds, which are often larger and there-
fore substantially increase intracranial pressure and require urgent 
neurosurgical evacuation. Large subdural and epidural bleeds 
are easier to evacuate because they occur outside of the brain 
tissue, whereas intra-parenchymal bleeds often occur deep within 
the brain tissue so it is difficult to evacuate them without causing 
further harm. Therefore, we may not be able to reliably exam-
ine the effect of tranexamic acid on subdural and epidural bleed 
expansion given that large bleeds are often evacuated before we 
can examine any effect of tranexamic acid on them. Including 
bleeds that may not be affected by tranexamic acid in the primary 
outcome would dilute any effect of tranexamic acid on intracra-
nial bleeding expansion to the null. Furthermore, when excluding 
patients who have undergone neurosurgery by the first rated 
post-randomisation scan, the proportional expansion of intra- 
parenchymal bleeding from pre- to post-randomisation is greater 
than for all other types of intracranial bleeding. Indeed, a recent 
randomised trial found a statistically significant reduction in 
intracerebral bleeding expansion with tranexamic acid24. Finally, 
intra-parenchymal bleeds are often spherical in shape, so there 
is less measurement error with the ABC/2 method of volume 
estimation compared to subdural and epidural bleeds, which 
have concave and convex shapes, respectively. For these reasons, 
the primary outcome will examine the effect of tranexamic acid 
on the total volume of intra-parenchymal bleeding.
In the original IBMS protocol18, the primary outcome included 
all patients randomised within 8 hours of injury. Since the pro-
tocol was published, an individual patient data meta-analysis 
was published which included 40,138 patients with acute severe 
bleeding enrolled in randomised trials of tranexamic acid25. This 
meta-analysis showed that immediate treatment improved the 
odds of survival by more than 70% (OR 1·72, 95% CI 1·42–2·10; 
p<0·0001). Thereafter, the survival benefit decreased by about 
10% for every 15 minutes of treatment delay until 3 hours, after 
which there was no benefit. To quantify any reduction in bleed-
ing volume with tranexamic acid compared to placebo in the 
IBMS, we must examine the primary outcome during the interval 
where bleeding is at greatest risk of expansion. If there is a minimal 
change in bleeding volume after three hours of injury, including 
patients treated after three hours of injury in the primary analysis 
will dilute any effect of tranexamic acid towards the null. There-
fore, we will restrict the analysis of the primary outcome to three 
hours of injury.
Secondary outcomes
(a)    Frequency and volume of progressive bleeding in 
patients randomised within 3 hours of injury: number 
of patients with a post-randomisation scan with a total 
bleeding volume of more than 25% of the volume on the 
pre-randomisation scan;
(b)    Frequency and volume of new bleeding in patients 
randomised within 3 hours of injury: number of patients 
with haemorrhage on the post-randomisation scan that 
was not seen on the pre-randomisation scan;
(c)    Number of patients with cerebral infarcts seen on a 
post-randomisation scan and not known to be present 
pre-randomisation;
(d)    Mean volume of intracranial bleeding seen after randomi-
sation in patients who undergo neurosurgical haemorrhage 
evacuation.
(e)    Composite poor outcome: progressive bleeding (“a” 
above), new bleeding (“b” above), cerebral infarction 
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(“c” above), death or the need for neurosurgery within 
28 days of injury.
All outcomes for patients treated after three hours of injury will 
be presented separately.
Trial status
We are currently collecting data for the IBMS and at the time 
of writing a total of 1,700 patients’ scans have been examined.
Statistical analysis plan
Trial profile
We will show the flow of trial patients in the Consolidated Stand-
ards of Reporting Trials (CONSORT) diagram. This will include 
the total number of patients randomised into the IBMS divided 
by treatment arm. Each treatment arm will detail the number 
of patients who received the loading and maintenance doses, 
the number of patients for whom clinical baseline and outcome 
data was collected, and the number of patients who were scanned 
before randomisation and/or after randomisation. We will report 
the number of patients included in the primary and secondary 
analyses, the reasons for any post-randomisation exclusions and 
the number lost to follow-up. If after a patient is randomised 
into the trial, it is found that they did not meet the eligibil-
ity criteria or did not receive their allocated treatment, they are 
considered to have deviated from the trial protocol. Data 
from patients who have deviated from the protocol will be 
included in the intention to treat analysis. If a patient or their 
representative withdraws consent for data collection, we will use 
only data up to the point of withdrawal in the analysis.
Baseline characteristics
We will report baseline characteristics, including, age, 
sex, GCS, systolic blood pressure, mean number of hours 
from injury to pre-randomisation scan, mean (and median) 
haemorrhage volume, different types of haemorrhage 
(intra-parenchymal, intra-ventricular, subdural, epidural, 
subarachnoid and petechial), cerebral infarction, oedematous 
lesions, mass effect findings, and the Marshall classification18. 
To check that randomisation produced similar groups, we will 
describe the baseline characteristics of each treatment group with 
frequencies and percentages.
Primary analysis
Linear mixed model26 will be used to compare the mean change 
in intra-parenchymal haemorrhage volume from pre- to post-
randomisation between treatment groups. The basic model 
includes pre- and post-randomisation volumes as correlated 
outcomes with mean post-randomisation volumes allowed to 
differ by treatment group but mean pre-randomisation volumes 
constrained to be the same, and with variances of pre- and post- 
randomisation volumes allowed to differ. In the absence of miss-
ing data, this linear mixed model gives identical estimates of 
the treatment effect, and near identical standard errors to the 
more standard ANCOVA analysis. The advantage of the linear 
mixed model approach is that patients with missing pre- or post- 
randomisation scans can be included in the analysis, potentially 
reducing bias and increasing efficiency26.
A linear regression analysis of the blinded data indicated that 
time from injury to CT scan, GCS, age and systolic blood pres-
sure are significantly predictive of the pre- and post-randomisation 
bleeding volumes (p<0.05). These covariates and the stratifica-
tion factor (treatment site)27 will be included in the analysis to 
improve the precision of the effect estimate. This will be done by 
extending the basic linear mixed model described above to 
include each covariate and its interaction with bleeding volume 
(pre- versus post-randomisation). This gives treatment effect 
estimates that are identical to those from the standard ANCOVA 
model in the absence of missing data. We expect the covari-
ates to affect bleeding volumes in different ways (e.g. older 
people are likely to have larger bleeds at baseline, more severely 
unconscious people (low GCS) are likely to have larger bleeds 
at baseline). In line with the CONSORT guidelines28, we will 
also report the results from the linear mixed model without 
covariate adjustment to facilitate synthesis and comparability 
with other trials that may not include the same covariates.
The blinded data indicates that pre- and post-randomisation 
bleeding volumes are positively skewed. We will log transform 
these values and report the primary outcome as a proportion.
In the original protocol, we planned to analyse the primary 
outcome using ANCOVA. Since publishing the protocol, we learnt 
that less than 50% of patients were scanned both pre- and post-
randomisation. Because the pre-randomisation mean bleeding 
volume of the observed data may be different from the true 
pre-randomisation mean bleeding volume, the estimates from the 
ANCOVA model may be biased. Compared to ANCOVA, linear 
mixed models are more powerful and typically less biased when 
there are missing data26.
Sensitivity analysis
Exclude patients who underwent neurosurgical haemorrhage 
evacuation after randomisation: The blinded data shows that 
after randomisation 14% of patients had neurosurgery before 
undergoing the first rated post-randomisation scan. In these cases, 
it is difficult to use the post-randomisation and post-neurosurgery 
scan to estimate the treatment effect because any change seen in 
intracranial haemorrhage expansion or infarction could be due 
to the effect of tranexamic acid or neurosurgery. The inclusion 
of these patients in the primary analysis may dilute any treat-
ment effect towards the null. Therefore, we will conduct 
a sensitivity analysis excluding patients who underwent 
neurosurgery before a post-randomisation scan was done.
Secondary analyses
Composite poor outcome, progressive haemorrhage, new haem-
orrhage, haemorrhagic oedematous lesions and mass effect: 
We will express the effect of tranexamic acid on the occurrence 
of dichotomous endpoints between trial arms, including the 
frequency of the composite “poor” outcome, progressive haemor-
rhage, new haemorrhage, haemorrhagic oedematous lesions, and 
mass effect outcomes (sulcal effacement, ventricular effacement, 
midline shift), using relative risks and 95% confidence inter-
vals estimated using generalised linear models. We will express 
the effect of tranexamic acid on the degree of midline shift 
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(measured in millimetres) using a basic linear mixed model, with 
pre-randomisation midline shift included as an outcome 
(as described above). We will extend this model to include 
covariates and their interaction with midline shift: time from 
injury to scan, GCS, age and systolic blood pressure.
Cerebral infarction: We will express the effect of tranexamic 
acid on cerebral infarcts measured at up to 28 days post- 
randomisation and not known to be present pre-randomisation 
using hazard ratios and 95% confidence intervals. We will 
conduct a survival analysis using the interval between the time of 
randomisation and the time of the scan on which the infarct 
was detected. We will plot the survival curves in the two treat-
ment groups using a Kaplan-Meier plot. The time to the scan 
on which the infarct was detected will be compared between 
treatment groups using a log-rank test. We will conduct a Cox 
regression analysis to quantify any difference between treatment 
groups in the hazard of detecting an infarct up to 28 days post- 
randomisation. We will conduct a sensitivity analysis excluding 
the patients who underwent neurosurgery.
Neurosurgical haemorrhage evacuation after randomisation: If 
tranexamic acid received soon after injury reduces intracra-
nial haemorrhage, a patient who received tranexamic acid 
may be less likely to undergo neurosurgery to evacuate haem-
orrhage compared with a patient who received placebo. 
However, in an emergency trauma setting, the decision for neu-
rosurgery occurs at the same time or very soon after the time of 
randomisation. Therefore, tranexamic acid received soon after 
injury may not affect the propensity for neurosurgery. But it 
could affect intracranial bleeding during neurosurgery.
We hypothesise that patients who receive tranexamic acid 
may have less blood on a post-randomisation and post- 
neurosurgery scan compared to patients who receive placebo. 
We will express the effect of tranexamic acid on the total volume 
of intracranial haemorrhage measured on a post-randomisation 
and post-neurosurgery scan using a linear mixed model as 
above. If the patient has been scanned pre-randomisation (and 
pre-neurosurgery), we will include the pre-randomisation 
bleeding volume as an outcome in the linear mixed model as 
above. To improve the precision of the effect estimate, we will 
extend this model to include each covariate and its interaction 
with bleeding volume: time from injury to scans, time from 
neurosurgery to scan, GCS, age and systolic blood pressure.
We will conduct a survival analysis using the time from 
randomisation to neurosurgery. The time to neurosurgery will 
be compared between treatment arms using a log-rank test. 
Because the log-rank test will only indicate whether there is a 
significant difference between treatment arms in the time to 
neurosurgery, we will also conduct a Cox regression analysis to 
quantify any difference in the hazard of neurosurgery between 
arms.
Subarachnoid haemorrhage: We will express the effect of 
tranexamic acid on the size (small-medium, large) and spread 
(focal-multiple, diffuse) of subarachnoid haemorrhage between 
trial arms, using relative risks and 95% confidence intervals 
estimated using generalised linear models.
Subgroup analyses
Time from injury to randomisation: Most intracranial bleed-
ing occurs within hours of injury5,25,29,30. Subgroup analyses will 
examine whether the effect of tranexamic acid on intracranial 
haemorrhage is modified by the time from injury to randomisa-
tion (≤1 hour, >1 to 3 hours, >3 to 8 hours). If there is minimal 
haemorrhage expansion after 3 hours25, we expect tranexamic 
acid will have a lesser effect in reducing haemorrhage expan-
sion in this group compared to the groups treated within 3 hours. 
We will conduct a linear regression analysis with an interaction 
between treatment (tranexamic acid, placebo) and time to 
randomisation (≤1 hour, 1–3 hours, >3–8 hours) to examine 
whether the effect of tranexamic acid on intracranial haemorrhage 
volume varies according to the time from injury to randomisation.
There may be an increase in the frequency of cerebral infarc-
tion with tranexamic acid in those treated after 3 hours of injury 
compared to those treated within 3 hours of injury15. We will 
use relative risks and 95% confidence intervals estimated using 
generalised linear models to examine whether the effect of tran-
examic acid on cerebral infarction varies within subgroups 
of time from injury to randomisation (≤3 hours, >3 hours). 
However, given the lower prevalence of cerebral infarction 
compared to intracranial bleeding, it will be difficult to reliably 
examine the effect of tranexamic acid on cerebral infarction 
within time strata. We will examine whether tranexamic acid 
increases the risk of adverse events in an individual patient 
data meta-analysis of 15,000 patients with TBI or spontaneous 
intracerebral haemorrhage (published separately)31.
Types of haemorrhage: We will conduct the linear mixed model 
analysis specified in the primary analysis section separately for 
subdural, epidural and intra-ventricular bleeds.
Missing data from scans not done before or after 
randomisation
Not all trial patients will be scanned before and after randomisa-
tion. We will report the number of patients without scans28 and 
baseline data for patients included in the analysis to help iden-
tify any selective missingness of outcomes by treatment arm32.
We will examine whether missing scans are missing equally 
between treatment arms and appear to be missing completely at 
random (MCAR). In this case, although missing data reduces the 
precision of the analysis, it does not bias the treatment effect33.
However, if haemorrhage expansion is associated with the reason 
the data are missing (patients with haemorrhage expansion may 
die before the second scan, patients without haemorrhage may not 
need to be re-scanned), imbalance in missing data by treatment 
arm can cause bias. We will examine whether the occurrence of 
missing scans is influenced by fully observed baseline variables 
(e.g. GCS), using relative risks and 95% confidence intervals 
estimated using generalised linear models. If they are, and 
within defined groups data are missing completely at random, 
the data could be missing at random (MAR)33. For example, if 
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missingness depends on GCS, but within mild, moderate and 
severe GCS groups missingness is unrelated to haemorrhage or 
infarction, the data are MAR. In this case, a regression analysis 
which takes GCS group into account should give unbiased 
estimates of the treatment effect34.
However, we suspect that within GCS groups, missingness could 
be related to haemorrhage volume (i.e. low GCS patients are 
expected to have a greater haemorrhage volume than high GCS 
patients). In this case, the data would be missing not at random 
(MNAR) (i.e. even when accounting for the fully observed 
data, the reason for missing observations still depends on the 
unseen values)33.
Because injury severity can partly explain missingness and there 
are unknown reasons for some missingness, it is difficult to 
confirm whether our missing data will be MAR or MNAR. For 
the purpose of the primary analysis, we will assume missing 
data are MAR. To examine how robust the primary analysis is 
to the chosen method of handling missing data, we will conduct 
sensitivity analyses assuming missing data are MCAR or MNAR. 
Under the MCAR assumption, we will compare haemorrhage 
volumes between treatment groups without accounting for 
missingness. Under the MNAR assumption, we will compare 
haemorrhage volumes between treatment groups and explore 
the possibility that missingness of the outcome data is related 
to prognostic characteristics as well as to the trial treatment. If 
tranexamic acid reduces intracranial haemorrhage expansion 
and the risk of death, patients who receive tranexamic acid may 
be more likely to be scanned post-randomisation compared to 
those who receive placebo. On the other hand, if tranexamic acid 
reduces or prevents intracranial haemorrhage expansion, post- 
randomisation scanning may not be clinically indicated in 
these patients. We will conduct sensitivity analyses excluding 
patients with a low pre-randomisation GCS who may have large 
haemorrhage expansion and therefore not survive to have a 
post-randomisation scan. We will conduct sensitivity analyses 
excluding patients with a high pre-randomisation GCS who 
may have smaller haemorrhage expansion and therefore not 
require a post-randomisation scan.
Between-centre effects
Randomisation into the CRASH-3 trial is stratified accord-
ing to participating centres. We do not expect between- 
centre differences in unfavourable outcome to affect the chance 
of demonstrating a treatment effect in TBI35. Nonetheless, for 
transparency we will report the interaction between centre and 
treatment effect using a linear mixed model with an interaction 
between centre and treatment.
Conclusion
This statistical analysis plan updates our previously published 
protocol18. The main changes are: an increased sample size 
from 1,000 to a maximum of 2,000 patients, a comparison of 
intra-parenchymal bleeding expansion between treatment groups 
for the primary outcome, the use of covariate adjusted linear mixed 
models for the primary analysis and relevant secondary analy-
ses, and restriction of the analysis of the primary and secondary 
outcomes (new and progressive bleeding) to patients treated 
within three hours of injury. We present our plan for the statistical 
analyses in advance of the database lock and un-blinding to guard 
against data dependent analyses. The CRASH-3 IBMS should 
provide reliable evidence on the effect of tranexamic acid on 
intracranial bleeding and infarction in TBI.
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